Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : WHO to start treatment with Merck's Ebola vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 04:56am EST

The World Health Organization said Thursday it plans to begin administering Ebola vaccine rVSV-ZEBOV (V920) in the Democratic Republic of the Congo "as soon as possible." WHO noted that 4,300 doses of the Merck & Co. Inc. (NYSE:MRK) vaccine are already in the region and an additional 7,540 doses are being shipped to the African nation.

The vaccine is being given as part of an expanded access protocol, according to Merck, which has a stockpile of more than 300,000 emergency use dose equivalents. WHO declared the situation an "outbreak" on May 8 (see BioCentury Extra, May 14).

WHO also reported on Thursday five additional Ebola cases, including one confirmed case in the Wangata health zone of Mbandaka, a city of nearly 1.5 million people. The two prior confirmed Ebola cases were in the town of Bikoro, about 150 km away from Mbandaka. So far, there have been 44 reported cases of Ebola virus disease.

rVSV-ZEBOV is a recombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein.

Final data from a 11,841-subject Phase III ring vaccination trial published in 2016 in The Lancet showed that rVSV-ZEBOV led to no Ebola cases after 10 or more days postvaccination compared with 23 cases in subjects who did not receive the vaccine. Subjects were followed for 84 days.

The vaccine was originally developed by the Public Health Agency of Canada, which retains non-commercial rights under a 2010 deal granting NewLink Genetics Corp. (NASDAQ:NLNK) rights to the product. Merck has exclusive, worldwide rights to develop, commercialize and manufacture the vaccine from NewLink under a 2014 deal (see BioCentury Extra, Nov. 24, 2014).

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.36% 75.87 Delayed Quote.-0.71%
NEWLINK GENETICS CORP 0.66% 1.52 Delayed Quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18MERCK AND : Mercks keytruda cuts death risk in oesophageal cancer
AQ
01/17Phoenix, Roche partner to develop TNBC biomarker
AQ
01/17EXELIXIS : enters crowded liver cancer field with Cabometyx, taking on Bayer, BM..
AQ
01/17PFIZER : BMS gets new OK for Opdivo/Yervoy in kidney cancer
AQ
01/16Bayer to increase patient access to specialty drugs with ZappRx digital platf..
AQ
01/16MERCK AND : KEYTRUDA Reduced Risk of Death by 31 Percent
AQ
01/16EISAI : Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA in Unres..
AQ
01/15MSKCC says senior execs may not hold industry board seats
AQ
01/14MERCK : Keytruda Reduced Risk of Death in Some Patients with Certain Advanced Ca..
DJ
More news
Financials ($)
Sales 2018 42 293 M
EBIT 2018 13 865 M
Net income 2018 7 942 M
Debt 2018 17 175 M
Yield 2018 2,60%
P/E ratio 2018 30,81
P/E ratio 2019 19,08
EV / Sales 2018 5,07x
EV / Sales 2019 4,77x
Capitalization 197 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 81,5 $
Spread / Average Target 7,5%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.71%197 291
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
AMGEN4.73%129 916